Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: A comparative study

Kim, Jeong Il; Kim, Seok Hyun; Lee, Byung Seok; Lee, Heon Young; Lee, Tae Hee; Kang, Young Woo; Lee, Hyang Ie; Kim, An Na; Nam, Soon Woo; Park, Byeong Chool; Chae, Hee Bok; Kim, Seok Bae; Song, Il Han; Park, Ji Young; Kim, Hong Su

doi:10.3350/kjhep.2008.14.4.493

Cited by 9 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The SVRs of genotype 1 group was reported to be very low at 13-14%,14,15 however, the SVR was relatively high at 20.8% in this study. This was consistent with the results of relatively high SVRs in Korean patients compared to those in Western countries in studies with patients who did not have liver cirrhosis, but the accurate reason is unknown 16,17. Furthermore, in this study, even the SVR rate of patients with portal hypertension who showed splenic enlargement in imaging study, thrombocytopenia, or esophageal or gastric varices in upper gastrointestinal endoscopy was 30.0% (9/30), which was better than the results of other studies.…”

Section: Discussionsupporting

confidence: 89%

“…This was similar to about 6.0-10.3% reported in domestic studies on chronic hepatitis C patients,16,17 but lower than 16.0-32.3% reported in studies on patients who were accompanied by compensated liver cirrhosis or portal hypertension 13,14. However, simple comparison is not warranted because this was a retrospective study, and there is the possibility that some of the 9 patients (10.5%) who were not followed up without particular reason may voluntarily discontinued the treatment due to other side effects than hematological adverse reactions.…”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis

et al. 2011

View full text Add to dashboard Cite

Background/AimsPegylated interferon (peginterferon) and ribavirin combination therapy is less effective and associated with a higher frequency of serious complications in chronic hepatitis C patients with cirrhosis than in noncirrhotic patients. This study evaluated the efficacy and tolerability of peginterferon and ribavirin treatment in patients with hepatitis C virus (HCV)-related cirrhosis.MethodsEighty-six patients with clinically diagnosed liver cirrhosis were treated with either peginterferon alpha-2a (n=51) or peginterferon alpha-2b (n=35) plus ribavirin. The sustained virologic response (SVR) and adverse effects were analyzed retrospectively.ResultsOf the 86 patients (55 males), 48 patients (55.8%) had HCV genotype 1 infection and 38 (44.2%) had genotype non-1 infection. The overall SVR rate was 34.9% (30/86), and the rates of SVR in the genotype 1 and non-1 patients were 20.8% (10/48) and 52.6% (20/38), respectively. The multivariate analysis revealed that having HCV genotype 1 (P=0.003) and high baseline viral load (>8.0×105 IU/mL, P=0.012) were the independent predictive factors for SVR failure. In 20.9% (18/86) of the patients, treatment was not completed due to adverse events (27.8%), loss to follow-up (50.0%), and other reasons (22.2%).ConclusionsPeginterferon and ribavirin combination therapy was relatively effective and feasible for clinically diagnosed HCV patients, especially in those with genotype non-1 infection and low baseline viral load.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 89%

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis

et al. 2011

View full text Add to dashboard Cite

show abstract

“…This was similar to the rates (5.8-10.3%) reported in South Korean studies of chronic hepatitis C patients 20-22. Among individuals with genotype 1 and genotype 2 or 3, more patients with advanced fibrosis discontinued treatment due to adverse events than ones without, but this is not statistically significant.…”

Section: Discussionsupporting

confidence: 85%

Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients

et al. 2013

View full text Add to dashboard Cite

Background/AimsChronic hepatitis C patients with advanced fibrosis have unsatisfactory sustained virological response (SVR) rates. Few data demonstrating the efficacy of combination therapy in chronic hepatitis C patients with advanced fibrosis in South Korea are available. The purpose of this study was to assess whether the stage of fibrosis impacts the efficacy of combination therapy for chronic hepatitis C.MethodsWe retrospectively reviewed data for a total of 109 patients with chronic hepatitis C, treated with peginterferon alfa and ribavirin. SVR according to the stage of liver fibrosis assessed by pretreatment liver biopsy and genotype results were analyzed.ResultsData from 66 genotype 1 patients (60.6%) and 43 genotype 2 or 3 patients (39.4%) among the 109 patients were analyzed. SVR rates for the genotype 1 patients were significantly lower for the stage 3-4 group (32.1%) than the stage 0-2 group (78.9%; P<0.001). SVR rates (92.0% for stage 0-2, 77.8% for stage 3-4, P=0.184) of genotype 2 or 3 patients were not significantly different according to fibrosis stage. Likewise, the frequency of adverse events was not significantly different according to fibrosis stage.ConclusionsCompared to patients without advanced fibrosis, we can anticipate good SVR rates for genotype 2 or 3 patients with advanced fibrosis and they did not show an inferior tolerability for peginterferon and ribavirin combination therpy. Our results suggest that active treatment is needed for genotype 2 or 3 patients with advanced fibrosis.

show abstract

“…Also, studies by Kim et al19 showed higher SVR rates in genotype 1 (59.3%) and genotype 2/3 (90.5%), higher than numbers drawn out in studies by Lee et al20: 68.4% in genotype 1 and 94.1% in genotype 2/3. However, SVR rates have been reported as 42-51% in genotype 1 and 76-82% in genotype 2/3 in Western countries 14-16…”

Section: Discussionmentioning

confidence: 70%

Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C

Jeong

Jung

Yang³

et al. 2012

Clin Mol Hepatol

View full text Add to dashboard Cite

Background/AimsSustained virologic response (SVR) for the treatment of chronic hepatitis C (CHC) may differ with ethnicity due to differences in genetic traits. This study evaluated the efficacy of peginterferon and ribavirin, and the association between IL28B genotypes and the treatment efficacy in Korean CHC patients.MethodsThis was a retrospective cohort study using data from medical records. Eighty-five CHC patients were eligible for assessment of the efficacy of antiviral therapy, and 47 patients were available for an IL28B genetic study, which was performed using the Multiplex tetra-primer PCR method for rs12979860.ResultsOverall, the early virologic response rate was 87.1%: 84.9% in HCV genotype 1 and 90.6% in genotype 2. The overall end-of-treatment virologic response rate was 81.2%: 75.5% in genotype 1 and 90.6% in genotype 2. The overall SVR rate was 81.2%: 75.5% in genotype 1 and 90.6% in genotype 2. For rs12979860, the frequencies of polymorphisms were 89% for the CC type, 11% for the CT type, and 0% for the TT type. Their overall SVR rate was 87% (39/47): 90.5% (38/42) for the CC type and 20% (1/5) for the CT type. For genotype 1, SVR rates were 88% (21/24) for the CC type and 0% (0/4) for the CT type. Multivariate analysis revealed that the IL28B-CC type was a good predictor for SVR.ConclusionsThe SVR of the combination therapy in Koreans was higher than that observed in Western countries. This finding might be attributable to the high prevalence of IL28B-CC type among Koreans, which may be a good predictor of SVR.

show abstract

Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: A comparative study

Abstract: We found no significant differences in therapeutic efficacies and adverse effects between the alpha-2a and -2b types of peginterferon as the initial treatment regimen in naive chronic hepatitis C patients.

Cited by 9 publications

References 15 publications

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis

Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients

Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C

Contact Info

Product

Resources

About